Merck KGaA is looking to sell its consumer healthcare business

By Catherine Sturman
It has recently been announced that European healthcare company Merck KGaA is looking to sell its consumer healthcare operations, or look at alternative...

It has recently been announced that European healthcare company Merck KGaA is looking to sell its consumer healthcare operations, or look at alternatives in which to develop further partnerships to provide the potential for further growth opportunities.

It’s long history, established back in the 17th century has seen it become one of the most well renowned consumer healthcare businesses in the world. The announcement has seen Merck’s shares soar by up to six percent.

A potential sell would enable Merck to further support its ongoing research into the development of new and existing prescription drugs within its biopharma channels to ensure it remains competitive throughout its strategic operations. To do so, further financial investment remains essential.

The company’s consumer healthcare provides sales of approximately $1BN per annum, making a potential sell a lucrative prospect for competitors.

Related stories

However, Belén Garijo, Member of the Executive Board of Merck KGaA, Darmstadt, Germany and CEO Healthcare commented in a press release: “We have maintained a solid position in attractive markets, and demonstrated a pattern of profitable growth.

We expect increasing internal constraints to fund the business to reach the required scale. Fully anticipating this, we are preparing strategic options.”

Merck currently focuses on consumer-centric solutions driven by global megatrends and achieved net sales of €860 million in 2016, cementing its position in new and emerging markets. However, its liquid crystals business is in decline, leading the company to look at further methods in which to remain competitive.

Additionally, whilst the company is looking to sell its consumer healthcare business, it has also recently acquired healthcare company Rigontec. Merck will provide a cash agreement of €115MN to Rigontec’s shareholders, and make additional contingent payments of up to €349MN.

Share

Featured Articles

Digital healthcare platform Balanced supports healthy ageing

10,000 people turn 65 in the USA each day. Digital healthcare platform Balanced wants to help them better manage healthy ageing, says CEO Katie Reed

TrueBinding’s antibody drugs fight Alzheimer’s Disease

Dongxu Sun, CEO at TrueBinding, shares how its research & antibody drug development is fighting illnesses such as Alzheimer’s Disease, stroke & more

Cardinal Health’s clinically integrated pharma supply chain

Peter J. Siavelis, SVP & General Manager, Health System & Provider Distribution & Services at Cardinal Health, discusses the integrated pharma supply chain

Healthcare Digital news roundup: digital healthcare & AI

Digital Healthcare

Hospitals must embrace IoMT device security

Hospitals

Mental health support for working women and mothers

Digital Healthcare